The new coronavirus disease (COVID-19) resulted in a pandemic in 2019 and encouraged researches worldwide to look for a treatment or a cure for this disease. As the risk of COVID-19 infection increases in people with concomitant comorbidities leading to the higher possibility to death due to the infection and increases the burden, it is essential to provide prophylaxis for patients who aren’t yet diagnosed and have a high risk of the infection especially in the early stages, as this is substantial in decreasing the onus on governments, health care system, and people who are at high risk especially hypertension and heart failure patients, because they are already on medications which might make the scenario worse One of the suggested promising medications is the renin inhibitor, Aliskiren, which was approved in 2007 for the treatment of hypertension. Several studies pointed out that Aliskiren can be used to prevent the virus from entering the host cells or at least prevent the disease from progressing into ARDS. Aliskiren inhibits renin and this will eventually result in the disruption of the renin-angiotensin system pathway that is suggested to be an entry point for the COVID-19. Some studies showed that this medication showed high affinity to the viral protease M pro which can be a target to terminate the replication of the virus in the host cells. This review article will highlight the suggested role of Aliskiren as a promising prophylactic and early stage treatment in ambulatory hypertensive patients who are at high risk for COVID-19.